Full
Outline
To observe the clinical effect of Changge Buyang Huanwu Decoction (菖葛补阳还五汤) combined with edaravone dexcamphorol in the treatment of acute cerebral infarction.
A total of 102 cases of acute cerebral infarction admitted from February 2022 to June 2024 were divided into western medicine group and combined decoction group by random number table method, with 51 cases in each group. The patients in the western medicine group were treated with edaravone dexcamphorol, while those in the combined decoction group were treated with Changge Buyang Huanwu Decoction combined with edaravone dexcamphorol, and the therapeutic effect of the two groups was evaluated. The self-care function of the patients was evaluated by Barthel index and the total score of TCM symptoms, the levels of interleukin-8 (IL-8), interleukin-10 (interleukin-10), hypersensitive C-reactive protein (hs-CRP) and other serum inflammatory factors, the changes of oxidative stress indexes such as superoxide dismutase (SOD) and malondialdehyde (MDA), the resistance index (RI), the changes in cerebral blood flow indexes such as cerebral blood volume (CBV), time to peak blood flow (TTP), homocystine (Hcy) and neuron-specific enolase (NSE) of the patients in both groups before and after treatment and the adverse reactions were compared.
Compared with that of the western medicine group (80.39%, 41/51), the index of the combined decoction group (96.08%, 49/51) was higher (P<0.05). Barthel index, total TCM symptom scores, the levels of IL-8, IL-10, hs-CRP, SOD and MDA, the values of RI, CBV, TTP, Hcy, NSE and other indexes were not significant between the two groups before treatment (P>0.05). After treatment, the levels of these indexes were improved in both groups and the results in the combined decoction group were all better than those in the western medicine group (P<0.05). There were fewer adverse reactions in the western medicine group and combined decoction group (P>0.05).
The combination of Changge Buyang Huanwu Decoction and edaravone dextrocamphorol exhibits the favorable clinical outcomes in the management of acute cerebral infarction. It effectively facilitates the rehabilitation, demonstrating safety and reliability, and thus merits the consideration for application.
80
11
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
